242 related articles for article (PubMed ID: 20336315)
41. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).
Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L
Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766
[TBL] [Abstract][Full Text] [Related]
42. Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice.
Shen X; Zheng JY; Shi H; Zhang Z; Wang WZ
Am J Med Sci; 2012 Jul; 344(1):52-8. PubMed ID: 22261621
[TBL] [Abstract][Full Text] [Related]
43. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro.
Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H
Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980
[TBL] [Abstract][Full Text] [Related]
44. Pyruvate kinase M knockdown-induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival.
Prakasam G; Singh RK; Iqbal MA; Saini SK; Tiku AB; Bamezai RNK
J Biol Chem; 2017 Sep; 292(37):15561-15576. PubMed ID: 28778925
[TBL] [Abstract][Full Text] [Related]
45. Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
Zou M; Hu X; Xu B; Tong T; Jing Y; Xi L; Zhou W; Lu J; Wang X; Yang X; Liao F
Oncol Rep; 2019 Feb; 41(2):989-998. PubMed ID: 30431119
[TBL] [Abstract][Full Text] [Related]
46. Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells.
Dong A; Kong M; Ma Z; Qian J; Cheng H; Xu X
Acta Biochim Biophys Sin (Shanghai); 2008 Jun; 40(6):497-504. PubMed ID: 18535748
[TBL] [Abstract][Full Text] [Related]
47. RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer.
Che C; Zhang L; Huo J; Zhang Y
Int J Clin Exp Pathol; 2015; 8(1):361-7. PubMed ID: 25755723
[TBL] [Abstract][Full Text] [Related]
48. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
49. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
[TBL] [Abstract][Full Text] [Related]
50. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
Sun Y; Chen Y; Xu M; Liu C; Shang H; Wang C
Biomed Res Int; 2020; 2020():9243681. PubMed ID: 32685545
[TBL] [Abstract][Full Text] [Related]
51. Exogenous p53 upregulated modulator of apoptosis (PUMA) decreases growth of lung cancer A549 cells.
Liu CJ; Zhang XL; Luo DY; Zhu WF; Wan HF; Yang JP; Yang XJ; Wan FS
Asian Pac J Cancer Prev; 2015; 16(2):741-6. PubMed ID: 25684518
[TBL] [Abstract][Full Text] [Related]
52. Dendrobine targeting JNK stress signaling to sensitize chemotoxicity of cisplatin against non-small cell lung cancer cells in vitro and in vivo.
Song TH; Chen XX; Lee CK; Sze SC; Feng YB; Yang ZJ; Chen HY; Li ST; Zhang LY; Wei G; Shi J; Xu K; Ng TB; Zhu LL; Zhang KY
Phytomedicine; 2019 Feb; 53():18-27. PubMed ID: 30668397
[TBL] [Abstract][Full Text] [Related]
53. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
[TBL] [Abstract][Full Text] [Related]
54. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
55. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
56. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
57. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice.
Lee I; Kalota A; Gewirtz AM; Shogen K
Anticancer Res; 2007; 27(1A):299-307. PubMed ID: 17352247
[TBL] [Abstract][Full Text] [Related]
58. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer.
Li D; Zhang Y; Xie Y; Xiang J; Zhu Y; Yang J
Cancer Gene Ther; 2013 Apr; 20(4):251-9. PubMed ID: 23470565
[TBL] [Abstract][Full Text] [Related]
59. Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct.
Zhao C; He J; Cheng H; Zhu Z; Xu H
J Exp Clin Cancer Res; 2016 Jul; 35(1):107. PubMed ID: 27371094
[TBL] [Abstract][Full Text] [Related]
60. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model.
Jiang QQ; Fan LY; Yang GL; Guo WH; Hou WL; Chen LJ; Wei YQ
BMC Cancer; 2008 Aug; 8():242. PubMed ID: 18706101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
